Ophthalmology Times

11/07/2025

Nanoscope Therapeutics has released positive long-term safety results from its EXTEND study, a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

The company noted that the EXTEND trial followed 10 patients with advanced retinitis pigmentosa (RP) who had previously received MCO-010. According to the company, the results showed that a single intravitreal injection of MCO-010 is safe and well-tolerated over 5 years, with no serious adverse effects or new safety signals. The safety profile of MCO-010 remained consistent between the phase 1/2a trial and the long-term follow-up period

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

11/06/2025

Ahead of the 2025 American Academy of Ophthalmology meeting held in Orlando, Florida, Johnson & Johnson marked a milestone with 100,000 of its TECNIS ODYSSEY IOLs having been implanted in patients’ eyes since the launch of the IOL in 2024. The IOL is described as a “diffractive full-range of vision (FVR) IOL with a violet-light filter.”

This announcement aligned with the presentation of clinical data by Karolinne M. Rocha, MD, PhD, at the AAO meeting. Rocha shared details from her presentation with Ophthalmology Times, highlighting the research into the tolerance of astigmatism and the visual symptoms of patients who received this diffractive FVR IOL with a violet-light filter

Johnson & Johnson reaches 100,000 TECNIS ODYSSEY IOLs implanted, and presented data on in vision correction and patient satisfaction at the AAO 2025 meeting.

11/06/2025

Sponsored by Harrow.

We believe in empowering physicians to treat based on need—not coverage. With VEVYE® Access For All, your eligible patients can access VEVYE® (cyclosporine ophthalmic solution) 0.1% for as little as $0 or $59 cash-pay through our partner, PhilRx.

No prior auths. No insurance hoops. Just straightforward access.


*For full terms and conditions visit https://hubs.li/Q03RC6tr0

11/06/2025

The SOL-R registrational trial (NCT06495918) of OTX-TKI (AXPAXLI) by Ocular Therapeutix has reached its randomization target of 555 patients.

The company describes AXPAXLI as an “investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties. It is currently being evaluated for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy, diabetic macular edema (DME), and other retinal diseases.”

The trial will be evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients.

11/05/2025

Avisi Technologies has released positive 12-month clinical data on the VisiPlate Aqueous Shunt from the VITA Trial. The VITA Trial is a prospective pilot study that was conducted at 3 centers by 3 separate implanting surgeons in South Africa.

The company describes the VisiPlate Aqueous Shunt as a “unique device made of a patented metamaterial that has been designed to be non-fibrotic and is many times thinner than a human hair,” and that its “redundant microchannels are engineered to provide sustained aqueous flow while minimizing the risk of blockage and re-intervention.”

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

11/05/2025

AAVantgarde Bio has announced the successful closing of a $141 million (€122 million) Series B financing round that was co-led by a new lead, Schroders Capital, as well as existing investors Atlas Venture and Forbion.

According to the company, the funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study assessing safety, tolerability, and preliminary efficacy of AAVB-039 in patients with Stargardt disease across 3 dose levels for Stargardt disease and the completion of the STELLA natural history study. The company is still recruiting for the STELLA study.

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study

11/04/2025

4D Molecular Therapeutics (4DMT) announced a strategic partnership with Otsuka Pharmaceutical to develop and commercialize 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) in the greater Asia-Pacific (APAC) region, including Japan.

According to the company, under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets. Additionally, Otsuka will lead all regulatory and commercialization activities in its licensed territories.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

11/04/2025

Viridian Therapeutics has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for veligrotug for the treatment of thyroid eye disease (TED).

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody. According to the company, it is a “novel, fully human monoclonal antibody [and] has demonstrated promising results in pivotal clinical studies, with data showing improvement in proptosis, diplopia, and other key measures of disease activity and was generally well tolerated.”

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody for the treatment of thyroid eye disease (TED).

11/03/2025

Catch up on all entries from our What If? series! Everything is available online now!

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

11/03/2025

Positive results from the ongoing Phase 2 OptimUM-09 trial are encouraging for the treatment of uveal melanoma (UM). According to the press release from IDEAYA Biosciences, the developers of this therapeutic candidate, “There are currently no approved systemic therapies for patients with primary UM, and there is a critical unmet need for new treatment options that reduce the risk of eye removal and vision loss and have the potential to delay or prevent progression to metastatic disease."

The results presented at 2025 European Society of Medical Oncology meeting support neoadjuvant darovasertib as a potential treatment to delay or prevent progression of the disease.

11/02/2025

SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP).

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months. Included in the study is a long-term follow-up period of 5 years. The company notes that safety and efficacy data will be collected over 2026 and 2027.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

11/01/2025

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

Stay tuned for more parts and see what you missed online!

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.